Greater efficacy and improved endothelial dysfunction in untreated type 2 diabetes with liraglutide versus sitagliptin

Dokkyo Journal of Medical Sciences

Volumn 41, Issue 3, 2014, Pages 211-220

  Suzuki, Kunihiro ^a   Tanaka, Seiichi ^a   Aoki, Chie ^a   Kato, Kanako ^a   Jojima, Teruo ^a   Aso, Yoshimasa ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitors; Flow mediated dilatation; Glucagon like peptide 1 receptor agonist; Liraglutide; Type 2 diabetes

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; C PEPTIDE IMMUNOREACTIVITY INDEX; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 84919761987     PISSN: 03855023     EISSN: 09115900     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14, 2010.
2. Whiting DR, Guariguata L, Weil C, Shaw J: IDF diabetes atlas:global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321, 2011.
3. Guariguata L: By the numbers:new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract 98: 524-525, 2012.
4. de Heer J, Rasmussen C, Coy DH, et al: Glucagon-like peptide-1, but not glucose-dependent insulinotro-pic peptide, inhibits glucagon secretion via somatosta-tin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51: 2263-2270, 2008.
5. Balas B, Baig MR, Watson C, et al: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92: 1249-1255, 2007.
6. Drucker DJ, Nauck MA: The incretin system: gluca-gon-like peptide-1 receptor agonist and dipeptidyl peptidase- 4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006.
7. Kolterman OG, Buse JB, Fineman MS, et al: Synthetic exedin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subject with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089, 2003.
8. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 109: 27-32, 2004.
9. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
10. Szabo C: Role of nitrosative stress in the pathgenesis of diabetic vascular dysfunction. Br J Pharmacol 156: 713-727, 2009.
11. Inzucchi SE, Bergenstal RM, Buse JB, et al: Management of hyperglycemia in type 2 diabetes: A patient-centered approach:position statement of the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD). Diabetes Care 35: 1364-1379, 2012.
12. Treatment Guide for diabetes 2012-2013, Japan Diabetes Society, Bunkodo, P 17-18.
13. Yoshioka N, Ishii H, Tajima N, et al: Curr Med Res Opin 30: 177-183, 2013.
14. Hertz RP, Unger AN, Lustik MB: Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 27: 1064-1073, 2005.
15. Buse JB, Rosenstock J, Sesti G, et al: Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47, 2009.
16. Drucker DJ, Sherman SI, Gprelick FS, et al: Incretin based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33: 428-433, 2010.
17. Astrup A, Carraro R, Finer N, et al: Safety, tolerabili-ty and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int Obes (Lond) 36: 843-854, 2012.
18. Liu H, Dear AE, Knudsen LB, et al: A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201: 5966, 2009.
19. Arakawa M, Mita T, Azuma K, et al: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like pep-tide-1 receptor agonist, exendin-4. Diabetes 59: 1030-1037, 2010.
20. Han L, Yu Y, Wang B: Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 97: 453-460, 2012.
21. van Poppel PC, Netea MG, Smits P, et al: Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 34: 2072-2077, 2011.
22. Matsubara J, Sugiyama S, Akiyama E, et al: Dipeptidyl sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77: 1337-1344, 2013.
23. Treatment Guide for diabetes 2012-2013, Japan Diabetes Society, Bunkodo, P 25-26.
24. Voidonikola PT, Stamatelopoulos KS, Alevizaki M, et al: The association between glycemia and endothelial function in nondiabetic individuals:the importance of body weight. Obesity 12: 2658-2662, 2008.
25. Nochioka K, Tanaka S, Miura M, et al: Ezetimibe improves endothelial function and Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J 76: 2023-2030, 2012.
26. Corretti MC, Anderson TJ, Benjamin EJ, et al: Guidelines for the ultrasound assessment of endothelial-de-pendent flow-mediated vasodilation of the brachial ar-tery:a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39: 257-265, 2002.
27. Matsuo S, Imai E, Horio M, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.
28. Meier JJ, Menge BA, Breuer TG, et al: Functional assessment of pancreatic beta-cell area in humans. Diabetes 58: 1595-1603, 2009.
29. Saisho Y, Kou K, Tanaka K, et al: Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 8: 315-322, 2011.
30. Okuno Y, Komada H, Sakaguchi K, et al: Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes. Metabolism 13: 1470-1476, 2013.
31. Knudsen LB: Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 47: 4128-4134, 2004.
32. Rollin B, Larsen MO, Gotfredsen CF, et al: The long-acting GLP-1 derivate NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrino Metab 283: E745-752, 2002.
33. Bregenholt S, Moldrup A, Blume N, et al: The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Byophys Res Commun 330: 577-584, 2005.
34. Vilsboll T, Krarup T, Deacon CF, et al: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613, 2001.
35. Xu L, Man CD, Charbonnel B, et al: Effect of sita-gliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes:a model-based approach. Diabetes Obes Metab 10: 1212-1220, 2008.
36. Gabor A, Henry R, Ratner R: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono):a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481, 2009.
37. Seino Y, Rasmussen MF, Nishida T, et al: Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26: 1013-1022, 2010.
38. van Poppel PC, Netea MG, Smits P, et al: Vilda-gluptin improves endothelium-dependent vasodilata-tion in type 2 diabetes. Diabetes Care 34: 2072-2077, 2011.
39. Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular risk. Circulation 6: 640-642, 2002.
40. DeFronzo RA, Okerson T, Viswanathan P, et al: Effect of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying and caloric intake:a randomized, cross-over study. Curr Med Res Opin 24: 2943-2952, 2008.
41. Shah Z, Pineda C, Kampfrath T, et al: Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 55: 2-9, 2011.
42. Gaspari T, Liu H, Welungoda I, et al: A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 8: 117-124, 2011.
43. Hopkins ND, Cuthbertson DJ, Kemp GJ, et al: Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes Metab 15: 770-773, 2013.
44. Fadini GP, Agostini C, Sartore S, et al: Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194: 46-54, 2007.
45. Golpon HA, Puechner A, Welte T, et al: Vasorelaxant effect of glucagon-like peptide-(7-36)amide and am-ylin on the pulmonary circulation of the rat. Regul Pept 102: 81-86, 2003.
46. Ozyazgan S, Kutluata N, Afsar S, et al: Effect of glucagon-like peptide-1 (7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide diabetic rats. Pharmacology 74: 119-126, 2005.
47. Vilsboll T, Zdravkovic M, Le-Thi T, et al: Liraglu-tide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lower body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30: 1608-1610, 2007.
48. Jelsing J, Vrang N, Hansen G, et al: Liraglutide: short-lived effect on gastric emptying — long lasting effects on body weight. Diabetes Obes Metab 14: 531-538, 2012.
49. Nauck MA, Kemmeries G, Holst JJ, et al: Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60: 1561-1565, 2011